{
  "meta": {
    "id": "test70",
    "title": "Pharmacotherapy Of Osteoporosis",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Following drugs increase bone resorption except:",
      "options": [
        {
          "label": "A",
          "text": "Corticosteroids",
          "correct": false
        },
        {
          "label": "B",
          "text": "Furosemide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hydrochlorothiazide",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hypervitaminosis D",
          "correct": false
        }
      ],
      "correct_answer": "C. Hydrochlorothiazide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Hydrochlorothiazide Hydrochlorothiazide (HCTZ) is a thiazide-type diuretic. Thiazides have several metabolic effects contributing to higher serum calcium levels, but increased renal tubular reabsorption of calcium resulting in reduced urine calcium excretion is the most likely cause . It decreases bone  resorption. Serum calcium concentrations are increased independently of PTH levels.</p>\n<p><strong>Highyeild:</strong></p><p>Influences affecting bone turnover \u2191 Resorption \u2193 Resorption Corticosteroids Androgens/Estrogens Parathormone Calcitonin Thyroxine (excess) Growth hormone Hypervitaminosis D Bisphosphonates Prostaglandin E2 Fluoride Interleukin 1 & 6 Gallium nitrate Alcoholism Mithramycin Loop diuretics Thiazide diuretics</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Options A, B, and D cause increased bone resorption.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bbb949f1",
      "audio": ""
    },
    {
      "text": "Which of the following conditions Bisphosphonates are not used?",
      "options": [
        {
          "label": "A",
          "text": "Malignancy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Paget's disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Postmenopausal osteoporosis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypervitaminosis D",
          "correct": true
        }
      ],
      "correct_answer": "D. Hypervitaminosis D",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Hypervitaminosis D Treatment of hypervitaminosis D does not include Bisphosphonate. As Bisphosphonate acts on the osteoclast , which is not the site of the defect in hypervitaminosis D.</p>\n<p><strong>Highyeild:</strong></p><p>Bisphosphonates e.g., ALENDRONATE PAMIDRONATE RISEDRONATE ZOLEDRONATE (zoledronic acid) - IV route Uses DOC for osteoporosis (Senile, steroid-induced, post-menopausal) Hypercalcemia of Malignancy Delays Osteolytic Bone Metastasis in breast cancer Prevents postmenopausal Osteoporosis Paget\u2019s disease of bone Osteolytic bone metastasis Mechanism of action: Inhibits activation of osteoclasts. And inhibits cholesterol biosynthesis in osteoclasts by inhibition of Farnesyl pyrophosphate ADRs IV zoledronate : Infusion reaction Nephrotoxicity Oral Bisphosphonates : Gastritis Esophageal erosion Instructions take medicine empty stomach with a full glass of water Not take any food/beverage for 30 mins Not to lie down for 30 mins Osteonecrosis of Jaw bone Increased risk of femoral fracture</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Options A, B, and C are an indication to use Bisphosphonates.</p>\n<p><strong>Extraedge:</strong></p><p>Hypervitaminosis D It may occur due to chronic ingestion of large doses (~50,000 IU/day) or due to increased sensitivity of tissues to vit D. Manifestations are due to elevated plasma calcium and its ectopic deposition. These are hypercalcemia , weakness, fatigue, vomiting, diarrhea, sluggishness, polyuria, albuminuria, ectopic Ca2+ deposition (in soft tissues, blood vessels, parenchymal organs), renal stones or nephrocalcinosis, hypertension, growth retardation in children. Even a coma has been reported. Treatment: consists of withholding the vitamin , a low calcium diet, plenty of fluids, and corticosteroids. Recovery may be incomplete in many cases</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "36dbb040",
      "audio": ""
    },
    {
      "text": "A drug that is known to cause osteonecrosis on IV administration is:",
      "options": [
        {
          "label": "A",
          "text": "Zoledronate",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tamoxifen",
          "correct": false
        },
        {
          "label": "C",
          "text": "Calcitriol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Strontium ranelate",
          "correct": false
        }
      ],
      "correct_answer": "A. Zoledronate",
      "question_images": [
        "https://dbmi-data.s3.ap-south-1.amazonaws.com/photos-1687759633854-QTDJ069003IMG1.JPG"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Zoledronate Is a bisphosphonate that is given by the I.V. route and can cause Osteonecrosis of the jaw bone.</p>\n<p><strong>Highyeild:</strong></p><p>Bisphosphonates e.g., ALENDRONATE PAMIDRONATE RISEDRONATE ZOLEDRONATE (zoledronic acid) - IV route Uses DOC for osteoporosis (Senile, steroid-induced, post-menopausal) Hypercalcemia of Malignancy Delays Osteolytic Bone Metastasis in breast cancer Prevents postmenopausal Osteoporosis Paget\u2019s disease of bone Osteolytic bone metastasis Mechanism of action: Inhibits activation of osteoclasts. And inhibits cholesterol biosynthesis in osteoclasts by inhibition of Farnesyl pyrophosphate ADRs IV zoledronate : Infusion reaction Nephrotoxicity Oral Bisphosphonates : Gastritis Esophageal erosion Instructions take medicine empty stomach with a full glass of water Not take any food/beverage for 30 mins Not to lie down for 30 mins Osteonecrosis of Jaw bone Increased risk of femoral fracture</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Options B, C, and D are not known to cause osteonecrosis .</p>\n<p><strong>Extraedge:</strong></p><p>Bisphosphonates inhibit bone resorption by causing osteoclast cell apoptosis, impairing the osteoclast\u2019s resorptive capacity , and preventing osteoclast formation. They have a high affinity for bone minerals and accumulate mainly in the sites of osteoclast activity. Without resorption and new bone formation , old bone survives beyond its lifespan , and its capillary network is not maintained, leading to avascular necrosis of the jaw .</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "399b43b0",
      "audio": ""
    },
    {
      "text": "The following are the practical points while taking bisphosphonates orally:",
      "options": [
        {
          "label": "A",
          "text": "Patient should be standing or sitting while taking it",
          "correct": false
        },
        {
          "label": "B",
          "text": "After administration, the patient should not lie down for at least one half-hour with Alendronate, risedronate, or one hour with ibandronate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Preferably to be taken with 240 ml of water",
          "correct": false
        },
        {
          "label": "D",
          "text": "To be taken 30 minutes after food with a full glass of water",
          "correct": true
        }
      ],
      "correct_answer": "D. To be taken 30 minutes after food with a full glass of water",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>To be taken 30 minutes after food with a full glass of water To be taken 30 minutes after food with a full glass of water oral Bisphosphonates: this is an incorrect statement as bisphosphonates have very poor bioavailability when taken orally . Therefore, they should be taken empty stomach.</p>\n<p><strong>Highyeild:</strong></p><p>Bisphosphonates e.g., ALENDRONATE PAMIDRONATE RISEDRONATE ZOLEDRONATE (zoledronic acid) - IV route Uses DOC for osteoporosis (Senile, steroid-induced, post-menopausal) Hypercalcemia of Malignancy Delays Osteolytic Bone Metastasis in breast cancer Prevents postmenopausal Osteoporosis Paget\u2019s disease of bone Osteolytic bone metastasis Mechanism of action: Inhibits activation of osteoclasts. And inhibits cholesterol biosynthesis in osteoclasts by inhibition of Farnesyl pyrophosphate ADRs IV zoledronate : Infusion reaction Nephrotoxicity Oral Bisphosphonates : Gastritis Esophageal erosion Instructions take medicine empty stomach with a full glass of water Not take any food/beverage for 30 mins Not to lie down for 30 mins Osteonecrosis of Jaw bone Increased risk of femoral fracture</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Options A, B, and C are correct statements about Bisphosphonates.</p>\n<p><strong>Extraedge:</strong></p><p>Oral Bisphosphonates : Gastritis Esophageal erosion Instructions take medicine empty stomach with a full glass of water Not take any food/beverage for 30 mins Not to lie down for 30 mins</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "abdaa127",
      "audio": ""
    },
    {
      "text": "Among the following options, Strontium ranelate works by which of the following mechanisms?",
      "options": [
        {
          "label": "A",
          "text": "Increases bone formation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreases bone resorption",
          "correct": false
        },
        {
          "label": "C",
          "text": "Both A and B",
          "correct": true
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "C. Both A and B",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Both A and B Strontium ranelate works by dual mechanism.</p>\n<p><strong>Highyeild:</strong></p><p>Strontium ranelate: It inhibits bone resorption by preventing osteoclast differentiation and promoting their apoptosis . In addition, it stimulates bone formation. In clinical trials, it has been found to increase bone mineral density and to decrease the risk of vertebral as well as hip fracture. However, it can increase the risk of serious cardiovascular diseases like MI, stroke, and thromboembolism. Therefore, it is indicated only as a reserve drug for severe osteoporosis in elderly women and in men at high risk of fracture in whom Bisphosphonates and other drugs are contraindicated or not tolerated. Other adverse effects are headaches, g.i. upset, rashes, and serious skin reactions. Dose: 2 g/day ; avoid food for 2 hours before and after the dose.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Options A and B. Option C is the better Option: D is incorrect.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "832efca4",
      "audio": ""
    },
    {
      "text": "Among the following options, Denosumab is used in:",
      "options": [
        {
          "label": "A",
          "text": "Osteoid osteoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Osteoporosis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Osteoarthritis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Osteomalacia",
          "correct": false
        }
      ],
      "correct_answer": "B. Osteoporosis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Osteoporosis Denosumab decreases bone resorption and is used in the treatment of Osteoporosis.</p>\n<p><strong>Highyeild:</strong></p><p>Denosumab: It is a fully human monoclonal antibody against RANKL . RANK ligand-Receptor activator of nuclear factor kappa beta (NFkB)ligand. By binding to and neutralizing RANKL, denosumab prevents RANK activation thereby inhibiting proliferation and differentiation of osteoclast precursors as well as osteoclast function. As a result, bone resorption is inhibited to an extent equal to or greater than potent It is now being used as a treatment option for osteoporosis in both women and men, as well as to limit bony metastasis in breast and prostate cancers. The bone loss caused by gonadal suppression therapy of these tumors is also counteracted. In osteoporotic patients with high fracture risk, denosumab has been found to lower vertebral as well as hip fracture risk by 40\u201368%. It can be given to patients with severe renal disease, in whom Bisphosphonates are contraindicated. Adverse effects of denosumab are flu-like symptoms, initial fall in serum Ca2+ level , dermatitis, susceptibility to infections (because RANKL is a signal molecule for many immune cells as well), and rare osteonecrosis of the jaw. Dose: 60 mg, S.C. once every 6 months (max. 3\u20135 years).</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Options A, C, and D are not an indication for Denosumab.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8107c745",
      "audio": ""
    },
    {
      "text": "Among the following options, Subcutaneous Calcitonin is used in which of the following conditions?",
      "options": [
        {
          "label": "A",
          "text": "Osteomalacia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Osteoporosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hypercalcemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Paget's disease",
          "correct": true
        }
      ],
      "correct_answer": "D. Paget's disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Paget's disease Subcutaneous Calcitonin 100 IU i.m./s.c. Daily or on alternate days is used in Paget\u2019s disease .</p>\n<p><strong>Highyeild:</strong></p><p>Calcitonin Uses - Hypercalcaemic states - Hyperparathyroidism, hypervitaminosis D, osteolytic bony metastasis, and hypercalcemia of malignancy; 4\u20138 IU/kg m. 6\u201312 hourly only for 2 days. It acts rapidly within 4 hours, the response peaks at 48 hours, and then refractoriness develops. It also relieves bone pain. For emergency treatment of hypercalcemia 5\u201310 IU/ kg may be diluted in 500 ml saline and infused i.v. over 6 hours. Calcitonin is a relatively weak hypocalcaemic drug . Therefore, it is used only to supplement Bisphosphonates initially , because BPNs take 24\u201348 hours to act. Loop diuretics are also used. Postmenopausal osteoporosis A nasal spray formulation delivering 200 IU per actuation has been employed in osteoporosis. One spray in an alternate nostril daily has been shown to increase bone mineral density in menopausal women and to reduce vertebral , but not nonvertebral , It is less effective than BPNs/HRT. However, British guidelines no longer recommend the use of calcitonin for postmenopausal osteoporosis, because the risk of malignancy associated with its long-term use outweighs the benefit. Paget\u2019s disease 100 IU m./s.c. daily or on alternate days produces improvement for a few months. Later, resistance usually develops due to the production of Bisphosphonates are preferred; calcitonin may be used as an adjuvant or 2nd line drug. Diagnosis of medullary carcinoma of the thyroid Detection of the high blood level of calcitonin is diagnostic of this tumor, which arises from the calcitonin-producing parafollicular cells of the thyroid.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Osteomalacia- it is a vitamin D deficiency. Calcitonin has no role in the treatment of Osteomalacia. Option: B. Osteoporosis-Nasal spray formulation of Calcitonin is used. Option: C. Hypercalcemia-diluted intravenous infusion of Calcitonin is used.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f74d246d",
      "audio": ""
    },
    {
      "text": "Which of the following statements is incorrect about Raloxifene?",
      "options": [
        {
          "label": "A",
          "text": "It is an estrogen partial agonist in the bone and cardiovascular system",
          "correct": false
        },
        {
          "label": "B",
          "text": "An antagonist at the breast and agonist at the endometrium",
          "correct": true
        },
        {
          "label": "C",
          "text": "Has high affinity for both ER? and ER?",
          "correct": false
        },
        {
          "label": "D",
          "text": "Used in the prevention and treatment of osteoporosis in postmenopausal women",
          "correct": false
        }
      ],
      "correct_answer": "B. An antagonist at the breast and agonist at the endometrium",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>An antagonist at the breast and agonist at the endometrium Raloxifene is a Selective estrogen receptor modulator (SERM) used to treat and prevent Postmenopausal osteoporosis. This SERM has a different pattern of action than It is an estrogen partial agonist in bone, lipid metabolism, and the cardiovascular system, but an antagonist in the endometrium and breast. It has a high affinity for both ER\u03b1 and ER\u03b2 and has a distinct DNA target , the \u2018raloxifene response element\u2019 (RRE).</p>\n<p><strong>Highyeild:</strong></p><p>Selective estrogen receptor modulator (SERM) Antagonistic nature Agonistic nature A. Treatment of breast cancer 1. Premenopausal age- given for 5 yrs 2. Postmenopausal age- given for 2 yrs and replaced with an aromatase inhibitor. 3. Male breast cancer Bone decrease bone resorption used in osteoporosis liver increase clotting factors ADR-Venous thromboembolism B.Peripheral tissue ADR-hot flushes Endometrium Endometrial hyperplasia Endometrial cancer Blood component decreases LDL cardioprotective (not that useful) Examples- \u25cf Tamoxifen \u25cf Raloxifene(Antagonist at endometrium) \u25cf       Bazedoxifene \u25cf Ospemifene-decreases vaginal dryness \u25cf Ormeloxifene (Centchroman saheli )-Contraception</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Options A, C, and D are true statements about Raloxifene.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1a53e6c0",
      "audio": ""
    },
    {
      "text": "The drug used in osteoporosis which act by increasing bone formation is:",
      "options": [
        {
          "label": "A",
          "text": "Raloxifene",
          "correct": false
        },
        {
          "label": "B",
          "text": "Teriparatide",
          "correct": true
        },
        {
          "label": "C",
          "text": "Denosumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Alendronate",
          "correct": false
        }
      ],
      "correct_answer": "B. Teriparatide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Teriparatide Teriparatide is the only agent which stimulates new bone formation , whereas the other three only check bone resorption .</p>\n<p><strong>Highyeild:</strong></p><p>Teriparatide- This recombinant preparation of 1\u201334 residues of the amino-terminal of human PTH has been recently introduced for the treatment of severe osteoporosis. It duplicates all the actions of the long (1\u201384) PTH. Injected S.C. 20 mg once daily, it acts only for 2\u20133 hours and has been found to increase bone mineral density in osteoporotic women. The effect was faster and more marked than that produced by estrogens and bisphosphonates (BPNs). Teriparatide stimulates new bone formation. In clinical trials, it was found to be equally or more effective than estrogens and BPNs in reducing the risk of vertebral as well as non-vertebral fractures in osteoporotic women as well as After c. Injection its plasma t\u00bd is 1 hr. When given only once daily , the action produced is intermittent, and the bone-forming action predominates over bone-resorbing High cost and need for daily s.c. injections are the limitations. Its use may be justified in severely osteoporotic women, those who have already suffered osteoporotic fractures or have multiple risk factors for fracture. Treatment with teriparatide beyond 2 years is not recommended , but BPNs may be continued thereafter. Side effects include dizziness, headache, and leg cramps. Paget's disease and hypercalcemia are the contraindications. Diagnostic use To differentiate pseudo from true hypoparathyroidism Teriparatide is given I.V. , if the plasma calcium level fails to rise , then it is pseudohypoparathyroidism.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Options A, C, and D. are used in osteoporosis and they act by decreasing bone resorption.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6dfe4781",
      "audio": ""
    }
  ]
}